{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:05:37Z","timestamp":1786989937860,"version":"build-2736575974"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.gore.2025.101791","type":"journal-article","created":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T17:40:05Z","timestamp":1750614005000},"page":"101791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Exacerbation of paraneoplastic cerebellar degeneration by immune checkpoint inhibitor use in endometrial cancer"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3300-5791","authenticated-orcid":false,"given":"Michael","family":"Danziger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Tymon-Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2025.101791_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: Cancer J. Clin."},{"key":"10.1016\/j.gore.2025.101791_b0010","first-page":"12","article-title":"Cancer statistics","volume":"74","author":"Siegel","year":"2024","journal-title":"CA: A Cancer J. Clin."},{"key":"10.1016\/j.gore.2025.101791_b0015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Levine","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.gore.2025.101791_b0020","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer\u2014combined analysis of the PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.gore.2025.101791_b0025","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in patients with microsatellite instability\u2013high advanced endometrial cancer: results from the KEYNOTE-158 study","volume":"40","author":"O\u2019Malley","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2025.101791_b0030","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.gore.2025.101791_b0035","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer","author":"Mirza","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.gore.2025.101791_b0040","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","author":"Eskander","year":"2023","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.gore.2025.101791_b0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2022.05.003","article-title":"Immunotherapy toxicities: an SGO clinical practice statement","volume":"166","author":"O\u2019Cearbhaill","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2025.101791_b0050","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1474-4422(23)00369-1","article-title":"Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes","volume":"23","author":"Farina","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.gore.2025.101791_b0055","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.gore.2025.101791_b0060","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41571-019-0194-4","article-title":"Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors","volume":"16","author":"Graus","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.gore.2025.101791_b0065","article-title":"Paraneoplastic cerebellar degeneration in platinum-responsive endometrial cancer: a case report and review of literature","volume":"37","author":"Liontos","year":"2021","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.gore.2025.101791_b0070","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1212\/01.wnl.0000407657.51588.5a","article-title":"Paraneoplastic cerebellar degeneration","volume":"77","author":"Peterson","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.gore.2025.101791_b0075","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40673-015-0034-y","article-title":"Guidelines for treatment of immune-mediated cerebellar ataxias","volume":"2","author":"Mitoma","year":"2015","journal-title":"Cerebellum Ataxias"}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235257892500116X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235257892500116X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T14:19:08Z","timestamp":1766413148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235257892500116X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":15,"alternative-id":["S235257892500116X"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2025.101791","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exacerbation of paraneoplastic cerebellar degeneration by immune checkpoint inhibitor use in endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2025.101791","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101791"}}